10 hasil untuk "Xiuning Le"
Menampilkan 1–10 · 0,48 detik · RSS
-
Artikel Jurnal Teks lengkap
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation, growth, and metastatic spread. The vascular network within the tumor facilitates the transport of nutrients…
-
Artikel Jurnal Teks lengkap
AI in drug discovery and its clinical relevance
The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation in clinical settings is a long, complex, and expensive process, with many potential points of failure. Over the past decade, a vast growth…
-
Artikel Jurnal
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream…
-
Artikel Jurnal Teks lengkap
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Abstract Epidermal growth factor receptor ( EGFR ) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC) 1–3 . Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations 4–6 . However…
-
Artikel Jurnal Teks lengkap
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
BACKGROUND: occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of…
-
Artikel Jurnal Teks lengkap
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in…
-
Artikel Jurnal Teks lengkap
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
-
Artikel Jurnal Teks lengkap
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer